Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Conditions
Interventions
Ciprofloxacin DPI (BAYQ3939)
Placebo
Locations
151
United States
Jasper, Alabama, United States
Flagstaff, Arizona, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Fort Smith, Arkansas, United States
Los Angeles, California, United States
Start Date
May 2, 2013
Primary Completion Date
March 9, 2016
Completion Date
March 9, 2016
Last Updated
January 24, 2018
NCT06166056
NCT02779478
NCT07274631
NCT07289464
NCT06670937
NCT07192705
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions